Abarca-Romero JE, García-García BA, Maya-Rivera AL

Language: Spanish
References: 10
Page: 20-24
PDF size: 245.52 Kb.

ABSTRACT

Organ transplantation represents the only definitive therapeutic option for patients with end-stage organ failure. This option has demonstrated its effectiveness and its positive impact on the health and economic systems. It is estimated that a multi-organ donor has the potential to benefit 7 or more recipients. Countries such as Spain and Portugal (with 30 to 40 donors per million inhabitants per year) have placed great importance on meeting the therapeutic goals of donors (MTD) during preservation therapy (PT) in Brain Death Donors (DME), all this due to the large number of complications inherent to this clinical condition that put the loss of these donors at risk. Although there is no established consensus of the BAT, there are proposals prepared by the Organ Procurement Organizations (OPOs) such as the United Network For Organ Sharing (UNOS) and the medical management forum to optimize the potential of the organ donor (Forum of Medical Management to Optimize Donor Organ Potential [FMMODOP], which have shown greater benefits with respect to the number of organs procured per donor. Because Mexico has a low donation rate (0.01 to 9.9 donors per million inhabitants), it is important that the management of DME is guided by the therapeutic goals proposed by the OPOs to avoid requesting organs that can be procured, considering the experience of the Hospital of specialties "Dr. Antonio Fraga Mouret" from the "La Raza" National Medical Center (HECMNR) in the area of cadaveric donation the present study seeks to evaluate the preservation therapy assigned to the DME in order to determine if the MTD established by the OPOs were achieved.

REFERENCES

1. Young TS, Greer DM. Brain Death and Management of a Potential Organ Donor in the Intensive Care Unit, Crit Care Clin. 2014; 30 (4), 813-831. Available in: https://doi.org/10.1016/j.ccc.2014.06.010

2. Global Observatory on Donation and Transplantation. International Report on Organ Donation and Transplantation Activities Executive summary 2017. Disponible en: //www.transplant-observatory.org/wp-content/uploads/2019/11/glorep2017.pdf

3. Wong J, Tan HL, Goh JPS. Management of the brain dead organ donor. Trends in Anaesthesia and Critical Care. 2017; 13: 6-12. Available in: https://doi.org/10.1016/j.tacc.2016.11.004

4. Centro Nacional de Trasplantes. Estado Actual de Receptores, donación y Trasplantes en México 3er Trimestre 2019. CENATRA. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/500964/3erTrimestre2019.pdf

5. Sally M, Malinoski D. Current Research on Organ Donor Management: Anesthesiology Clinics. 2013; 31 (4): 737-748. Available in: https://doi.org/10.1016/j.anclin.2013.08.004

6. Anwar T, Lee JM. Medical Management of Brain-Dead Organ Donors. Acute and Critical Care. 2019; 34 (1): 14-29. Available in:https://doi.org/10.4266/acc.2019.00430

7. Plurad DS, Bricker S, Falor A et al. Donor hormone and vasopressor therapy: Closing the gap in a transplant organ shortage: Journal of Truma Acute Care Surg. 2012; 73 (3): 689-694. Available in: https://doi.org/10.1097/TA.0b013e318250b122

8. Plurad DS, Bricker S, Neville A et al. Arginine vasopressin significantly increases the rate of successful organ procurement in potential donors. American J Surg. 2012; 204 (6): 856-861. Available in: https://doi.org/10.1016/j.amjsurg.2012.05.011

9. Salim A, Martin M, Brown C et al. The Effect of a Protocol of Aggressive Donor Management: Implications for the National Organ Donor Shortage. The Journal of Trauma, Injury, Infection, and Critical Care. 2006; 61 (2): 429-435. doi: 10.1097/01.ta.0000228968.63652.c1.

10. Shemie SD, Ross H, Pagliarello J et al. Organ donor management in Canada: recommendations of the forum on Medical Management to Optimize Donor Organ Potential. CMAJ. 2006; 174 (6): S13-S32. Available in: https://doi.org/10.1503/cmaj.045131